Considering that small molecule compounds targeting HDACs are currently undergoing clinical trials for the treatment of cancer and metabolic diseases, a better understanding of HDAC6-dependent cellular processes would be highly valuable for the evaluation of the clinical relevance and therapeutic efficacy of HDAC6 inhibitors. This evidence concerns the gene HDAC6 and cancer.